Sign in Subscribe
Cancer

Circulating Tumor DNA Monitoring Reveals Molecular Progression in Advanced Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Research conducted by a team from the University of Copenhagen has shed light on the potential of liquid biopsy in monitoring treatment response and early detection of treatment failure in advanced non-small cell lung cancer (NSCLC) patients. The study aimed to investigate the clinical validity of circulating tumor DNA (ctDNA) treatment monitoring in a real-life cohort of advanced NSCLC patients. The researchers found that ctDNA monitoring leads to earlier detection of treatment failure, clarifies the majority of non-conclusive radiologic evaluations, and has the potential to spare patients from likely futile treatments and adverse events.

Key Takeaways:

  • The study included 150 advanced NSCLC patients who underwent ctDNA treatment monitoring during their first-line treatment.
  • Cancer-specific mutations and longitudinal plasma sampling were present in 132 of the 150 patients.
  • CtDNA was detectable in 88 (67%) of the 132 patients treated with chemotherapy, immunotherapy, or combination treatment.
  • In 66 (90%) of the 73 patients experiencing progressive disease, a ctDNA increase was observed with a median lead time of 1.5 months before radiologic progression.
  • Overall, 119 (33%) of the 365 treatment cycles were administered after molecular progression.
  • CtDNA measurements could clarify the results in 38 (79%) of the 48 non-conclusive radiologic evaluations.
  • The researchers concluded that ctDNA monitoring has the potential to spare patients from likely futile treatments and adverse events.

Statistics:

  • 132 of 150 patients (88%) had cancer-specific mutations and longitudinal plasma sampling.
  • 88 (67%) of the 132 patients treated with chemotherapy, immunotherapy, or combination treatment had detectable ctDNA.
  • In 66 (90%) of the 73 patients experiencing progressive disease, a ctDNA increase was observed with a median lead time of 1.5 months.
  • 119 (33%) of the 365 treatment cycles were administered after molecular progression.
  • 38 (79%) of the 48 non-conclusive radiologic evaluations were clarified by ctDNA measurements.

Sources:

  • "Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients." Cancer Research Communications, 2022.
  • University of Copenhagen.
  • American Association for Cancer Research (AACR).
  • ORCID profiles for authors: Malene Stochkel Frank (orcid.org/0000-0002-8179-7108), Niels Pallisgaard (orcid.org/0000-0002-0749-0810), Uffe Bodtger (orcid.org/0000-0002-1231-9209), Julie Gehl (orcid.org/0000-0003-3829-0210).

Read more